Cathie's Ark Logo
Exact Sciences Corp. Logo

ARKG Holdings of Exact Sciences Corp. (EXAS) - Updated Daily

Liquid BiopsyGenomicsGenetic Testing
Date
Direction
Shares
Fund Weight
Fund
June 2, 2023
SELL6.039k0.0245%ARKG
May 25, 2023
SELL8.540k0.0336%ARKG
May 24, 2023
SELL10.263k0.0407%ARKG
May 23, 2023
SELL28.203k0.1114%ARKG
May 22, 2023
SELL9.981k0.0424%ARKG

Key Statistics

⚖️Weighting🧢Market Cap
11.11%$15.13b
🏋🏿‍♂️Weight Rank In ARKG🌏Country
1🇺🇸United States
🏋️‍♀️Weight Rank Across All Funds💳ARK Estimated Cost Average
6$94.56
🎫ARK Ownership Percent
1.52%
Description
exact sciences is a molecular diagnostics company focused on colorectal cancer. the company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. stool-based dna (sdna) technology is included in the colorectal cancer screening guidelines of the american cancer society and the u.s. multi-society task force on colorectal cancer. for more information on exact sciences'​ noninvasive colon cancer screening test, visit cologuardtest.com
Website
exactsciences.com

Other ETFs That Hold EXAS

Ticker
NameWeight
ARKGARK Genomic Revolution ETF11.77%
ARKKARK Innovation ETF6.43%
XBISPDR® S&P Biotech ETF1.49%
AGNGGlobal X Aging Population ETF0.85%
LABUS&P Biotech Bull 3X Shares ETF0.209%

Research Notes and Commentary for EXAS

No Research Notes Found for EXAS